Ameriprise
YMAB

Ameriprise’s Y-mAbs Therapeutics YMAB Stock Holding History

Ameriprise’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-41,781
Closed -$228K – 3990
2023
Q3 		$228K Buy
41,781
+10,600
+34% +$61.7K ﹤0.01% 3661
2023
Q2 		$212K Buy
+31,181
New +$234K ﹤0.01% 3716
2023
Q1 		– Sell
-66,392
Closed -$325K – 4043
2022
Q4 		$325K Sell
66,392
-1,106
-2% -$8.04K ﹤0.01% 3560
2022
Q3 		$973K Sell
67,498
-2,036
-3% -$33.7K ﹤0.01% 3128
2022
Q2 		$1.05M Buy
+69,534
New +$811K ﹤0.01% 3101

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Ameriprise's YMAB Position: Q4 2023 in Review

Ameriprise sold out of Y-mAbs Therapeutics (YMAB) in Q4 2023, closing a stake of 41,781 shares — an estimated $228K sold.

Ameriprise first reported a position in YMAB in Q2 2022 and held it in 5 quarters. The position peaked at $1.05M in Q2 2022. 94 funds tracked by Wall St. Rank hold YMAB as of Q4 2023.

  • Ameriprise reported no remaining Y-mAbs Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Ameriprise sold 41,781 Y-mAbs Therapeutics shares in Q4 2023, an estimated $228K.
  • Ameriprise first reported a position in Y-mAbs Therapeutics in Q2 2022 and held it in 5 quarters.
  • Ameriprise's Y-mAbs Therapeutics position peaked at $1.05M in Q2 2022.
  • 94 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2023.

Based on Ameriprise's 13F filing for Q4 2023, filed 14 Feb 2024.